The Tylenol Crisis: How Johnson & Johnson Saved a Brand After Seven Deaths

In late September 1982, a 12-year-old girl in a Chicago suburb died after taking an Extra-Strength Tylenol capsule. Within days, six more people in the area had died. Investigators discovered that Tylenol capsules had been laced with potassium cyanide.

The deaths caused national panic. Tylenol was the best-selling painkiller in the United States. Now its name was on the news beside the word “poison.”

How Johnson & Johnson responded became the most-cited example of crisis management in business history.

The Context

Tylenol, made by Johnson & Johnson’s McNeil Consumer Products, had become the leading over-the-counter painkiller in the US. It held around 35% of the market and was one of J&J’s most profitable products.

The poisonings were not caused by a manufacturing fault. Someone had taken bottles from shops, added cyanide to the capsules and put them back on shelves. The killer was never identified.

J&J faced a choice. It could argue that the problem was limited to the Chicago area and that the company was not to blame. Or it could act as if the whole country was at risk.

The Campaign

J&J, led by CEO James Burke, chose to act broadly and quickly.

Recall. The company recalled around 31 million bottles of Tylenol from shops across the country, at a reported cost of about $100 million. It stopped all advertising for the product.

Warning the public. J&J issued warnings through the media, advising people not to take Tylenol capsules until the situation was understood. It set up hotlines for worried consumers.

Openness with the media. Burke and other executives spoke to the press regularly. They appeared on TV news programmes and answered difficult questions. The company worked closely with police and federal agencies.

Exchange offer. J&J offered to replace Tylenol capsules that people had already bought with tablets, which were harder to tamper with.

Relaunch. In November 1982, about six weeks after the deaths, J&J reintroduced Tylenol in new triple-sealed packaging: a glued box, a plastic seal around the cap and a foil seal over the mouth of the bottle. The relaunch was supported by advertising, discount coupons and presentations to doctors and pharmacists.

J&J’s approach was unusual for the time. Many companies faced with a crisis would have waited for more information, limited the recall to the affected area or stayed silent to avoid legal risk. J&J’s lawyers and some advisers reportedly worried that a national recall would suggest the company was at fault. Burke decided that protecting customers mattered more than those concerns.

The media played a central role. The story dominated news coverage for weeks, and J&J chose to work with journalists rather than avoid them. Burke appeared on programmes such as “60 Minutes” and “The Phil Donahue Show,” explaining what the company was doing and why. This helped ensure that the public saw J&J as a victim of a crime and a responsible company, rather than as the cause of the deaths.

The relaunch was carefully planned. J&J’s sales force made many presentations to medical professionals to rebuild confidence. The company offered coupons worth a few dollars to encourage people to buy the product again. The new packaging was highlighted in advertising and on shelves, so consumers could see the difference.

Why It Worked

Safety came first. The recall showed the public that J&J cared more about people’s lives than about its profits. That built trust at a moment when trust was badly damaged.

The company was guided by its values. J&J had a written credo that put responsibility to customers first. Burke later said the credo made the decision to recall clear.

Communication was honest and fast. J&J did not hide or minimise the problem. It kept the public informed, which reduced rumours and fear.

It fixed the problem. Tamper-resistant packaging addressed the real risk. The relaunch was not just a return to shelves but a visible improvement.

It relaunched quickly. Coming back within weeks, rather than months, meant that competitors had less time to take Tylenol’s customers permanently.

The Results

Tylenol’s market share collapsed after the deaths, falling from about 35% to under 10%. Many analysts predicted the brand would never recover.

It did. Within about a year, Tylenol had regained most of its market share. The brand survived and remained one of the best-known painkillers in the US.

The crisis changed the industry. In 1983, the US government introduced rules requiring tamper-resistant packaging for many over-the-counter medicines. Tampering itself became a federal crime.

The Tylenol case is taught in business schools around the world and is often held up as the model for crisis response. It is sometimes simplified into a story of perfect leadership, but it also involved hard choices, significant costs and some luck, including the fact that the tampering was clearly the act of an outsider rather than a flaw in the product.

Subsequent incidents tested the approach. In 1986, another death linked to tampered Tylenol capsules led J&J to stop selling capsules altogether and switch to caplets, which were harder to tamper with. Again, the company chose a costly step to protect customers. Over time, this consistent behaviour helped establish J&J’s reputation for putting safety first.

The Lesson for Today’s Marketers

In a crisis, act as though your customers’ safety is all that matters. J&J’s willingness to take a huge short-term cost built trust that paid off for decades.

Communicate openly and often. Silence or defensiveness creates suspicion. Visible leadership reassures people.

And fix the problem, not just the story. The Tylenol relaunch worked because the new packaging made the product safer. Good communication cannot replace real change.